New drug MAR002 aims to tame acromegaly in early trial
NCT ID NCT07641179
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests a new drug called MAR002 in 72 adults with acromegaly, a condition caused by a pituitary tumor that leads to too much growth hormone. Participants will receive either MAR002 or a placebo as injections under the skin. The study will check if the drug is safe and if it lowers IGF-1 levels, a key marker of the disease, over 10 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MAR002 (injected under the skin)
- What this could lead to
- If it works, this could point toward a new treatment option for acromegaly that helps control hormone levels and symptoms.
- What could go wrong
- This is an early Phase 2 trial with only 72 participants, so results may not apply to everyone. The drug may not work better than placebo or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACROMEGALY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Growth-Hormone blocker stay safe in everyday use? a korean study investigates
- Which intubation method works best for acromegaly patients?
- New octreotide pill faces off against current capsule in healthy volunteer study
- New software could improve acromegaly care
- Scientists hunt for hidden genes behind pituitary tumors
- New study tracks Octreotide's Real-World impact on acromegaly over two years